ClinicalTrials.gg
CompletedNCT02103283Updated Jun 25, 2025

A Phase 1, Open-Label Study of Teprotumumab in Patients With Diabetic Macular Edema (DME)

A Phase 1 interventional study of Teprotumumab in Diabetic Macular Edema, sponsored by Amgen. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-25.

Sponsored by Amgen · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 276 studies in Macular Edema with a site in United States — 16 open to participants now, 33 under way, 11 of them phase 3. Macular Edema · United States.

Enrollment
215th of 244
5 · median 45
Started
2014
with 14 others
Phase 1
43 of 276
3 open now
Registered
135th of 276
by date

Among the 276 studies in Macular Edema with a site in United States, this one is the 215th largest by enrollment of the 244 interventional ones that give a count, is one of 15 that started in 2014, is one of 43 in phase 1, and was the 135th registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 66 are open to participants now.

Browse Macular Edema studies →

Open to participants now

16 of the 276 studies in Macular Edema with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 44 Macular Edema studies recruiting now, 31 (70%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 276 studies in Macular Edema with a site in United States, or all of them as a file.
02

Study summary

A Phase 1 Study to evaluate the Safety of teprotumumab in Patients with Diabetic Macular Edema.

Read the detailed description

A Phase 1, Open-Label Safety and Pharmacodynamic Study of RV 001, an Insulin-Like Growth Factor-1 Receptor (IGF-1) Antagonist, Given By IV Infusion in Patients with Diabetic Macular Edema (DME).

03

Conditions studied

  • Diabetic Macular Edema

Browse trials for

Keywords

  • Diabetic Macular Edema
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of diabetes mellitus with \<8.5%
  • IGF 1 in serum > 106 ng/mL
  • Women of must have negative pregnancy test and be willing and able to use two different methods of , one of which must be oral contraceptive or depot formulation. Males must be surgically sterile or agree to use barrier contraception
  • DME of less than 12 months duration
  • Non-proliferative diabetic retinopathy of moderate severity
  • Best corrected electronic ETDRS letter score \< 78 and > 24

Exclusion criteria

Exclusion Criteria:

  • Unstable-uncontrolled diabetes as demonstrated by a change in diabetes medication greater than 15% in the previous 60 days.
  • Significant renal disease, myocardial infarction, stroke, , acute congestive heart failure
  • Blood pressure > 180/110
  • Anti-vascular endothelial growth factor (VEGF) treatment within two months prior to enrollment
  • History of pan retinal photocoagulation within four months prior to enrollment
  • History of ocular surgery within four months prior to enrollment
  • History of systemic treatment with within 3 months prior to enrollment
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    Teprotumumab

    Teprotumumab 20mg/kg administered by intravenous infusion every 3 weeks for 3 infusions

    Drug: Teprotumumab

Interventions

  • Teprotumumab 20mg/kg administered by intravenous infusion every 3 weeks for 3 infusions

    Also known as: RV 001

06

What researchers measure

Primary outcomes

  1. Safety of RV001in subjects with Diabetic Macular Edema

    Number of subjects with adverse events, serious adverse events and early discontinuations due to adverse events. Number of subjects with clinical significant abnormal laboratory values, electrocardiograms (pre and post infusions), abnormal vital signs, ophthalmic and physical examinations.

    Time frame: Change from Baseline to Week 9

Secondary outcomes

  1. Safety of RV001in subjects with Diabetic Macular Edema

    Pharmacodynamic measure includes change in Optical Coherence Tomography, Fluorescein Angiography and Stereoscopic color funds photos findings.

    Time frame: Change from Baseline to Week 9

07

Study locations

3 sites
  • David S Boyer
    Beverly Hills, California 90211, United States
  • David A Eichenbaum, MD
    St. Petersburg, Florida 33711, United States
  • Diana Do, MD
    Omaha, Nebraska 68106, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2014, a primary completion of Aug 2016 and a completion of Aug 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2014
First posted
Apr 3, 2014
Start
Oct 2014
Primary completionActual
Aug 2016
CompletionActual
Aug 2016
Last update
Jun 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02103283
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Apr 3, 2014
Start date
Oct 2014
Primary completion
Aug 2016
Completion
Aug 2016
Last update
Jun 25, 2025

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Teprotumumab

Start the discussion